American Research & Management Company’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $17K | Buy |
562
+63
| +13% | +$2.39K | ﹤0.01% | 267 |
|
|
2022
Q2 | $27K | Hold |
499
| – | – | 0.01% | 235 |
|
|
2022
Q1 | $27K | Hold |
499
| – | – | 0.01% | 242 |
|
|
2021
Q4 | $28K | Hold |
499
| – | – | 0.01% | 237 |
|
|
2021
Q3 | $24K | Sell |
499
-20
| -4% | -$1K | 0.01% | 248 |
|
|
2021
Q2 | $26K | Hold |
519
| – | – | 0.01% | 248 |
|
|
2021
Q1 | $23K | Buy |
519
+319
| +160% | +$14.5K | 0.01% | 240 |
|
|
2020
Q4 | $9K | Hold |
200
| – | – | ﹤0.01% | 296 |
|
|
2020
Q3 | $9K | Hold |
200
| – | – | ﹤0.01% | 266 |
|
|
2020
Q2 | $10K | Hold |
200
| – | – | ﹤0.01% | 268 |
|
|
2020
Q1 | $9K | Sell |
200
-80
| -29% | -$4.27K | ﹤0.01% | 260 |
|
|
2019
Q4 | $16K | Hold |
280
| – | – | ﹤0.01% | 252 |
|
|
2019
Q3 | $15K | Hold |
280
| – | – | ﹤0.01% | 261 |
|
|
2019
Q2 | $14K | Sell |
280
-800
| -74% | -$40.1K | ﹤0.01% | 279 |
|
|
2019
Q1 | $56K | Buy |
1,080
+800
| +286% | +$40K | 0.02% | 205 |
|
|
2018
Q4 | $13K | Sell |
280
-160
| -36% | -$7.88K | ﹤0.01% | 260 |
|
|
2018
Q3 | $22K | Hold |
440
| – | – | 0.01% | 238 |
|
|
2018
Q2 | $22K | Hold |
440
| – | – | 0.01% | 220 |
|
|
2018
Q1 | $21K | Hold |
440
| – | – | 0.01% | 245 |
|
|
2017
Q4 | $20K | Hold |
440
| – | – | 0.01% | 260 |
|
|
2017
Q3 | $22K | Hold |
440
| – | – | 0.01% | 227 |
|
|
2017
Q2 | $24K | Hold |
440
| – | – | 0.01% | 212 |
|
|
2017
Q1 | $23K | Sell |
440
-40
| -8% | -$2.03K | 0.01% | 205 |
|
|
2016
Q4 | $23K | Hold |
480
| – | – | 0.01% | 221 |
|
|
2016
Q3 | $26K | Hold |
480
| – | – | 0.01% | 218 |
|
|
2016
Q2 | $26K | Hold |
480
| – | – | 0.01% | 207 |
|
|
2016
Q1 | $24K | Hold |
480
| – | – | 0.01% | 215 |
|
|
2015
Q4 | $24K | Sell |
480
-100
| -17% | -$5.1K | 0.01% | 215 |
|
|
2015
Q3 | $28K | Hold |
580
| – | – | 0.01% | 211 |
|
|
2015
Q2 | $30K | Hold |
580
| – | – | 0.01% | 211 |
|
|
2015
Q1 | $33K | Hold |
580
| – | – | 0.01% | 205 |
|
|
2014
Q4 | $31K | Hold |
580
| – | – | 0.01% | 203 |
|
|
2014
Q3 | $33K | Sell |
580
-80
| -12% | -$4.9K | 0.01% | 199 |
|
|
2014
Q2 | $44K | Buy |
660
+160
| +32% | +$10.8K | 0.02% | 189 |
|
|
2014
Q1 | $33K | Hold |
500
| – | – | 0.01% | 200 |
|
|
2013
Q4 | $33K | Hold |
500
| – | – | 0.01% | 198 |
|
|
2013
Q3 | $31K | Hold |
500
| – | – | 0.01% | 201 |
|
|
2013
Q2 | $31K | Buy |
+500
| New | +$31.7K | 0.01% | 195 |
|
Other funds holding GSK
American Research & Management Company's GSK Position: Q3 2022 in Review
American Research & Management Company increased its GSK (GSK) stake by 13% in Q3 2022, buying an estimated $2.39K and bringing the position to 562 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #267.
American Research & Management Company first reported a position in GSK in Q2 2013 and has held it in 38 quarters since. The position peaked at $56K in Q1 2019. 743 funds tracked by Wall St. Rank hold GSK as of Q3 2022.
- American Research & Management Company held 562 shares of GSK worth $17K as of Q3 2022.
- American Research & Management Company bought 63 GSK shares in Q3 2022, an estimated $2.39K.
- GSK made up ﹤0.01% of American Research & Management Company's portfolio in Q3 2022, its #267 holding.
- American Research & Management Company first reported a position in GSK in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's GSK position peaked at $56K in Q1 2019.
- 743 funds tracked by Wall St. Rank held GSK as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.